McQueen, R. Brett http://orcid.org/0000-0002-4302-2678
Baum, Seth J.
Louie, Michael J.
Sasiela, William J.
Bilitou, Aikaterini
Shah, Hemal
Nash, Beth
Gillard, Kristin K.
Ray, Kausik K.
Funding for this research was provided by:
Esperion Therapeutics
Article History
Accepted: 26 September 2022
First Online: 31 October 2022
Declarations
:
: Funding for this study was provided by Esperion Therapeutics, Inc., the manufacturer of bempedoic acid and the fixed-dose combination of bempedoic acid plus ezetimibe used in this study.
: R. Brett McQueen has received institutional funding to the University of Colorado from Real Endpoints, LLC. Seth J. Baum has received funding and/or consulting fees from Amgen, AstraZeneca, Axcella, Boehringer Ingelheim, Esperion, Lilly, Madrigal, and Novartis. Michael J. Louie is an employee of Esperion Therapeutics, Inc., and may own Esperion stock or stock options. William J. Sasiela is a former (retired) employee of and a current consultant for Esperion Therapeutics, Inc., and may own Esperion stock or stock options. Aikaterini Bilitou is an employee of Daiichi Sankyo Europe, GmbH, which has a corporate agreement with Esperion Therapeutics, Inc. Hemal Shah is an employee of Value Matters, LLC, and a consultant for Esperion Therapeutics, Inc. Beth Nash is a former employee and consultant of Real Endpoints, which received financial support for this study from Esperion Therapeutics, Inc. Kristin K. Gillard is an employee of Esperion Therapeutics and may own Esperion stock or stock options. Kausik K. Ray has received research grants from Amgen, Daiichi Sankyo, MSD, Pfizer, Regeneron, and Sanofi, and honoraria or consulting fees from Abbvie, Algorithm, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cerenis, Cipla, Esperion, IONIS, Kowa, Lilly, Medicines Company, MSD, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Silence Therapeutics, and Takeda.
: Not applicable.
: Not applicable.
: Not applicable.
: The data and model that produced the results are proprietary to Esperion Therapeutics, Inc.
: Not applicable.
: All authors meet the International Committee of Medical Journal Editors criteria for authorship for this article. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All authors designed the study, RBM conducted the analyses, and BN, HS, KKG, and RBM drafted the manuscript. All authors critically reviewed the manuscript for intellectual content and approved the final version of the manuscript.